Navigation Links
Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
Date:5/21/2010

periods should periodically reevaluate its long-term usefulness for the individual patient.

INTUNIV is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

INTUNIV should not be used in patients with a history of hypersensitivity to guanfacine or any of its inactive ingredients or by patients taking other products containing guanfacine.

Hypotension, bradycardia, and syncope were observed in clinical trials.  Use INTUNIV with caution in treating patients who have experienced hypotension, bradycardia, heart block, or syncope, or who may have a condition that predisposes them to syncope; are treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.  Heart rate and blood pressure should be measured prior to initiation of therapy, following dose increases, and periodically while on therapy.  Advise patients to avoid becoming dehydrated or overheated.

Sedation and somnolence were commonly observed in clinical trials.  The potential for additive sedative effects with CNS depressant drugs should be considered.  Patients should be cautioned against operating heavy equipment or driving until they know how they respond to INTUNIV.  Advise patients to avoid use with alcohol.

Common adverse reactions in patients taking INTUNIV that may be dose related over the range of 1 to 4 mg/day include somnolence, sedation, abdominal pain, dizziness, hypotension/decreased blood pressure, dry mouth, and constipation.

Please see accompanying Full Prescribing Information at

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
2. New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season
3. New Study Shows ENJUVIA® Significantly Reduced Sleep Time Awakenings Caused by Hot Flashes in Postmenopausal Women
4. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
5. Whistleblower Lawyers Comment on New England Journal of Medicine Study
6. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
7. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
8. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
9. Spiral Enteroscopy is Three Times Faster than Double-Balloon Enteroscopy in Diagnosing the Small Intestine, New Study Finds
10. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
11. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  Decision Resources Group finds ... eligible for biologic therapy, only a proportion ... gastroenterologists cite patients, discomfort with biological therapy ... rates, followed by cost-related issues and payer ... biologics, Janssen Biotech,s Remicade and AbbVie,s Humira ...
(Date:9/17/2014)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NasdaqGS: ... to contact Peretz Bronstein or his investor ... or 212-697-6484. The investigation focuses on ... federal securities laws. On September 16, 2014, ...
(Date:9/17/2014)... PRAIRIE, Minn. , Sept. 17, 2014 ... and global market leader of advanced imaging modalities for ... Ultrasound System in two live cases at the Transcatheter ... The cases were presented from Medstar Washington Hospital ... York-Presbyterian Hospital/Columbia University Medical Center ( New York, ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3
... , JERUSALEM , Jan. ... company, announced today that it has granted Novartis an option to ... Permeability Enhancer (TPE) technology for use with certain related small molecule ... a separate but related agreement, the MPM Bio IV NVS Strategic ...
... , FRANKLIN LAKES, N.J. , Jan. 19 ... scheduled to present at the following investor conferences: , Brian Griffin ... Global Healthcare Services Conference on Monday, January 25, 2010 at ... New York ; , David B. Snow Jr. , Medco chairman ...
Cached Medicine Technology:Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3Medco to Present at Upcoming Investor Conferences 2
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... first-of-its-kind research study was announced today that will ... impact long-term wellness and contribute to healthy aging. ... Center and funded through a $10 million unrestricted ... Fund, WELL aims to identify lifestyle and environmental ... and wellness as they age. WELL will be ...
(Date:9/17/2014)... September 17, 2014 In its latest blog ... and believes that having family close by during a stay ... not the process is successful, is highlighting a member of ... in the lives of addicts across the country and around ... therapy can reduce the blood pressure, heart rate, and stress ...
(Date:9/17/2014)... these sound like the ideas of a ... components of an exciting new approach to imaging ... of metastatic prostate cancer, scientists at Virginia Commonwealth ... Medicine and Johns Hopkins Medical Institutions have provided ... could revolutionize doctors, ability to see tumors that ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... of Economy, Vet Difficulties Demonstrate Urgency; Advances in ... Mental Health America, the country,s oldest and ... mentally healthier lives, today called for action on ... for Mental Health."To view the Multimedia News Release, ...
... Customers; Reaches 400,000 Live User Milestone; Named #1 SSO ... identity and access management (IAM) solutions are the most ... the best performance in the Company,s history. In ... new user licenses. In addition, the Company reached ...
... at the University of Texas Medical Branch at Galveston ... fever virus uses to disarm the defenses of infected ... in humans, inflicting liver damage, blindness and even death ... Rift Valley fever also afflicts cattle, goats and sheep, ...
... N.M., Feb. 17 Exagen Diagnostics, Inc., which ... for research and analytic specific reagents to clinical ... Alsobrook, Ph.D., has been named vice president and ... oversees Exagen,s day-to-day operations, company alliances and genomic ...
... Effect on Executive Function and Functional Capacity are ... According to a New Report from Decision ResourcesWALTHAM, ... the world,s leading research and advisory firms for ... drug were to receive formal regulatory approval for ...
... procedure rooms offer faster and more accurate diagnosis and ... Medical Center today announces the completion of its state-of-the-art ... Now located on the second level of the ... with three fully functional state-of-the-art catheterization labs (cath labs) ...
Cached Medicine News:Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 2Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 3Health News:Video: On 100th Anniversary, Mental Health America Declares 'It's Time for Mental Health' 4Health News:Sentillion Announces 2008 as the Best Year in the Company's History 2Health News:Sentillion Announces 2008 as the Best Year in the Company's History 3Health News:Scientists uncover secrets of potential bioterror virus 2Health News:Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 2Health News:A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 2Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 3Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 4Health News:St. Mary Medical Center Opens New Cardiovascular Catheterization Labs Reaffirming Role as a Regional Leader in Cardiovascular Medicine 5
... key clinical and economic issues of cerclage ... designed to maximize tension control while minimizing ... combines efficient instrumentation with a simple technique. ... is indicated for general orthopaedic trauma surgery ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... Many of DePuy's aggressive innovations have become ... to be equalled. The AML Total ... to efficiently address and effectively meet the ... arthroplasty. With greater than 15 years ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Medicine Products: